ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 632,08
1,24%
Dow Jones
39 308,00
-0,06%
DAX
18 374,53
1,22%
Brent Oil
86,91
0,54%
Bitcoin
60 285,99
-2,81%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Canadá
  5. TSX
  6. Medicenna Therapeutics Corp (MDNA)

  7. Medicenna Therapeutics Corp (MDNA) Actualités

MDNA

Medicenna Therapeutics (MDNA)

Medicenna Therapeutics Corp
De:
Trier par:
 Showing the most relevant articles for your search:TSX:MDNA
DateHeureSourceTitreSymboleSociété
26/04/202414h16PR Newswire (Canada)L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - MDNATSX:MDNAMedicenna Therapeutics Corp
26/04/202414h14PR Newswire (Canada)Canadian Investment Regulatory Organization Trade Resumption - MDNATSX:MDNAMedicenna Therapeutics Corp
26/04/202414h09PR Newswire (Canada)Suspension de la négociation par l'Organisme canadien de réglementation des investissements - MDNATSX:MDNAMedicenna Therapeutics Corp
26/04/202414h07PR Newswire (Canada)Canadian Investment Regulatory Organization Trading Halt - MDNATSX:MDNAMedicenna Therapeutics Corp
11/06/202013h00PR Newswire (Canada)Medicenna to Present at Raymond James Human Healthcare Innovation ConferenceTSX:MDNAMedicenna Therapeutics Corp
29/05/202014h15PR Newswire (US)Medicenna Presents Data on MDNA11, an IL-2 Superkine at ASCO 2020TSX:MDNAMedicenna Therapeutics Corp
29/05/202014h05PR Newswire (US)Medicenna Updates Efficacy Results from Phase 2b Recurrent GBM Trial at ASCO 2020TSX:MDNAMedicenna Therapeutics Corp
15/05/202013h30PR Newswire (US)Medicenna Announces March 31, 2020 Year-End ResultsTSX:MDNAMedicenna Therapeutics Corp
04/05/202013h00PR Newswire (Canada)Medicenna Announces Upcoming Presentations at the ASCO Annual MeetingTSX:MDNAMedicenna Therapeutics Corp
15/04/202015h23PR Newswire (Canada)Medicenna Announces Full Exercise of Over-Allotment Option as Part of $40.25 Million Public OfferingTSX:MDNAMedicenna Therapeutics Corp
25/03/202012h00PR Newswire (US)Medicenna's IL-2 Superkine, MDNA19, Demonstrates Best-in-Class Features in a Non-Human Primate StudyTSX:MDNAMedicenna Therapeutics Corp
17/03/202014h14PR Newswire (Canada)Medicenna Announces Closing of Public Offering of $35 MillionTSX:MDNAMedicenna Therapeutics Corp
12/03/202014h00PR Newswire (Canada)Medicenna Announces Intention to File Final Short Form ProspectusTSX:MDNAMedicenna Therapeutics Corp
04/03/202015h37PR Newswire (Canada)L'OCRCVM permet la reprise de la négociation - MDNATSX:MDNAMedicenna Therapeutics Corp
04/03/202015h36PR Newswire (Canada)IIROC Trade Resumption - MDNATSX:MDNAMedicenna Therapeutics Corp
04/03/202015h25PR Newswire (Canada)Medicenna Announces Pricing of $35 Million Overnight Marketed Offering of Common SharesTSX:MDNAMedicenna Therapeutics Corp
03/03/202023h14PR Newswire (Canada)Suspension de la négociation par l'OCRCVM - MDNATSX:MDNAMedicenna Therapeutics Corp
03/03/202023h11PR Newswire (Canada)IIROC Trading Halt - MDNATSX:MDNAMedicenna Therapeutics Corp
03/03/202022h35PR Newswire (Canada)Medicenna Announces Overnight Marketed Offering of Common SharesTSX:MDNAMedicenna Therapeutics Corp
13/02/202013h30PR Newswire (US)Medicenna Reports Third Quarter Fiscal 2020 Financial ResultsTSX:MDNAMedicenna Therapeutics Corp
13/01/202013h00PR Newswire (US)Medicenna Reports Compelling Results from Recurrent Glioblastoma Trial When Compared to an Eligibility-Matched Control ArmTSX:MDNAMedicenna Therapeutics Corp
08/01/202015h13PR Newswire (US)Medicenna Receives $1.3 Million Through Early Warrant ExercisesTSX:MDNAMedicenna Therapeutics Corp
12/12/201914h00PR Newswire (US)Medicenna Presents Additional Encouraging Phase 2b Clinical Data at the Inaugural Glioblastoma Drug Development Annual SummitTSX:MDNAMedicenna Therapeutics Corp
09/12/201913h30PR Newswire (US)Medicenna Announces Presentation of the MDNA55 Clinical Trial at the Inaugural Glioblastoma Drug Development Annual SummitTSX:MDNAMedicenna Therapeutics Corp
25/11/201913h30PR Newswire (US)Medicenna Reports Promising Efficacy in Phase 2b MDNA55 Clinical Trial at the Society for Neuro-Oncology Annual MeetingTSX:MDNAMedicenna Therapeutics Corp
21/11/201914h00PR Newswire (Canada)Medicenna Reports Improved Drug Distribution of MDNA55 with Novel Delivery Technology in Phase 2b Recurrent Glioblastoma Clin...TSX:MDNAMedicenna Therapeutics Corp
20/11/201914h00PR Newswire (US)Medicenna To Host Key Opinion Leader Call Focused on Latest MDNA55 Recurrent Glioblastoma Phase 2b Clinical Study ResultsTSX:MDNAMedicenna Therapeutics Corp
18/11/201913h00PR Newswire (Canada)Medicenna to Host a Key Opinion Leader Symposium on MDNA55 for Treatment of Recurrent GlioblastomaTSX:MDNAMedicenna Therapeutics Corp
14/11/201913h00PR Newswire (US)Medicenna Announces Presentations on MDNA55 Recurrent Glioblastoma Clinical Trial at the Annual Meeting of the Society of Neu...TSX:MDNAMedicenna Therapeutics Corp
05/11/201914h00PR Newswire (Canada)Medicenna Reports Second Quarter Fiscal 2020 Financial ResultsTSX:MDNAMedicenna Therapeutics Corp
 Showing the most relevant articles for your search:TSX:MDNA

Dernières Valeurs Consultées

LSE
AB48
Citi Fun 24
TSX
MDNA
Medicenna Therapeutics
BIT
UB2XSM
UniCredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés